When we considered all positive screens more than two years prior to clinical diagnosis in HCC cases to be false positive screens (definition C1) and fixed the screening-level FPR at 10%, we observed that 4.15%, 3.93% and 1.79% of patients have more than two false positive screening using the AFP only, AFP+Lab+ ΔAFP and PEB approach respectively. This evidence concerns the gene AFP and hepatocellular carcinoma.